Dermatosis perforante por gefitinib

Gefitinib [Iressa®] is a new antineoplastic agent that acts by selectively inhibiting epidermal growth factor receptor tyrosine kinase [EGFR-TK]. It has shown activity against several solid tumors. Because of their action mechanism, gefitinib and other tyrosine kinase inhibitors have been associated with multiple cutaneous effects, most of which are mild and well tolerated. We present a case of perforating dermatosis after treatment with gefitinib.